From: Terry S. Singeltary Sr. (
Subject: CJD/VACCINES/CHILDREN -- could the "V" in vCJD mean vaccine???
Date: September 5, 2000 at 1:17 pm PST

Hello Voice,

could the "V" in vCJD mean vaccine, instead of variant???

kind regards,
Terry S. Singeltary Sr.

######### Bovine Spongiform Encephalopathy

Greetings list members,

this document is very disturbing, considering if they continued to use
these vaccines, the U.K. could loose a generation of children. If they
continue to force these vaccines on children, they could loose more than
just one generation, looking at the inventory. I did not know, that a
Government body or bodies, if you include the United States, could be
so stupid to this disease, with the evidence they have to date.
It's as blatant and negligent as you can get. You may think the BSE
Inquiry is almost over, but that was only the beginning.

The Truth Will Come...
(just hope i'm alive to see it)

kind regards,
Terry S. Singeltary Sr., Bacliff, Texas USA

BSE3/1 0250

Dr Harris (MED)

From: Dr Adams (MB3B)

cc - Dr. Pickles

Date: 14 February 1989


This minute details the information received on human vaccines in
response to telephone enquires, and details of forthcoming expert
group meetings during February 1989.


We have contacted all the major vaccine product licence holders whose
products are likely to be used in children. Many manufacturers use
bovine material. As can be seen, this information is diverse and
incomplete. Each company stressed that they could not give an accurate
assessment without detailed researches, given the complexity of
sourcing/purchasing arrangements.

All the licences are detailed in appendix 1; the overview is as follows;

1. XXXXXXXXXXX have polio, measles, mumps, rubella, rotavirus vaccines.
AlL use bovine serum from a UK source and bovine commercial product from
unknown source. Some agent comes from the USA and New Zealand.

2. XXXXXXXXXXX (see Appendix 2). All their vaccines apart from yellow
fever, cholera and typhoid contain bovine material:

--Oral polio; up to 1988, foetal calf serum was used from UK and New
Zealand (pooled); since 1988 foetal calf serum only from New Zealand.
Large stocks are held.

--Rubella; bulk was made before 1979 from foetal calf serum from UK
and New Zealand. None has been made as there are some 15 years stock.

--Diphtheria; UK bovine beef muscle and ox heart is used but since the
end of 1988 this has been sourced from Eire. There are 1,250 litres
of stock.

--Tetanus; this involves bovine material from the UK mainly Scottish.
There are 21,000 litres of stock.

--Pertussis; uses bovine material from the UK. There are 63,000 litres
of stock.

--They consider that to switch to a non-UK source will take a minimum
of 6-18 months and to switch to a non-bovine source will take a minimum
of five years.

3. XXXXXXXXXXX have measles, mumps, MMR, rubella vaccines. These are
sourced from the USA and the company believes that US material only is


BSE3/1 0251

4. XXXXXXXXXXX have a measles vaccine using bovine serum from the UK.
there are 440,000 units of stock.
--They have also got MMR using bovine serum from the UK.

5. XXXXXXXXXXX have influenza, rubella, measles, MMR vaccines likely to
be used in children. Of those they think that only MMR contains bovine
material which is probably a French origin.

6. XXXXXXXXXXX have diphtheria/tetanus and potasses on clinical trial.
These use veal material, some of which has come from the UK and has
been made by XXXXXXXXXXX (see above).

7. XXXXXXXXXXX have influenza vaccines which are made up in egg medium.

8. XXXXXXXXXXX The Secretary of State has a number of licences. We
understand that the inactivated polio vaccine is no longer being used.
There is a stock of smallpox vaccine. We have not been able to determine
the source material. (Made in sheep very unlikely to certain bovine

9. XXXXXXXXXXX have acellular triple vaccine in which material of
UK bovine source has been used.

As far as I can see, XXXXXXXXXXX are the sole supplier of pertussis
vaccine which uses bovine casein digest.

You should also be aware that DH has made arrangements for meningococal
vaccine to be available, on a named patient basis, from
XXXXXXXXXXX and XXXXXXXXXXX. Both companies use bovine media in

Expert Group Meetings

The Veterinary Products Conmmittee will discuss the proposed draft
guidelines and significance thereof to veterinary vaccine products
at 2.00pm on Thursday 16 February 1989 with professor Armo in the
Chair. (See appendix for VPC Committee constitution).

The Human & Veterinary Medicines Working Group re BSE will meet on
22 February at 10.00am Market Towers. The meeting will be to provide
expert information to CSM on the 23 February in the light of the
Southwood report and concerns about vaccines. In addition to Department
of Health and MAFF officials, Professor Collee, Dr Schild, Dr Minor,
Dr Tyrell from the Biologicals Subcommittee will be present,
Dr Kimberlin and Dr Martin and Mr Wilesmith have been invited.
Professor Collee will be in the Chair.

The Committee on Safety of Medicines will meet on the 23 February. They
will consider advice from the working group, draft guidelines for the
industry, a draft letter to product licence holders of human medicines,
and recommendations regarding priority actions on particular product

MAFF briefing note is added at Appendix 6.




don't think it is not possible, just take a look here, are some fine
examples of transmission of TSE's via VACCINES...TSS

The large number of cases (1040), temporal clustering of the
outbreaks (15 in the first 6 months of 1997), the high in-flock
incidence, and the exceptional involvement of goats (390 cases),
suggested an accidental infection. The source of the
epidemic might have been TSE-contaminated meat and bonemeal, but
eight flocks had never been fed any commercial
feedstuff. Infection might have risen from the use of a formol-
inactivated vaccine against contagious agalactia prepared by a
single laboratory with brain and mammary gland homogenates of sheep
infected with Mycoplasma agalactiae. Although
clinical signs of TSE in the donor sheep have not been found, it
is possible that one or more of them were harbouring the
infectious agent. Between 1995 and 1996, this vaccine was given
subcutaneously to 15 of the affected flocks (to one flock in
1994); in these animals the disease appeared between 23 and 35
months after vaccination. No information is available for
herd 13 because it was made up of stolen animals. Sheep from the
remaining three flocks (1-3, figure) did not receive the
vaccine, thus suggesting a naturally occurring disease.

1: Dev Biol Stand 1996;88:237-41

Transmissible encephalopathies and biopharmaceutical production.

Robinson MM

USDA-ARS Animal Disease Research Unit, Washington State University,
Pullman, USA.

The use of post-mortem tissues as sources for the production of
biologicals, vaccines and feedstuffs has led to the transmission
or generation of transmissible encephalopathies in some recipients.
For example, the use of pituitary-derived human growth hormone and
gonadotropins has resulted in the transmission of Creutzfeldt-Jakob
disease to other humans [1], the use of formalin-inactivated sheep
brain as a source for louping ill vaccine led to the transmission of
scrapie to over 1,000 sheep from one vaccine lot [2], and the use
of rendered products from ruminant carcasses in the domestic animal
food chain led to the emergence and epizootic of bovine spongifrom
encephalopathy in the United Kingdom [3]. Infection with
transmissible encephalopathies by iatrogenic or other
mechanisms is difficult to
predict or control. The characteristics of these pathogens do not
permit easy detection, clearance, or inactivation in routine
biopharmaceutical production environments.

Publication Types:
Review, tutorial

PMID: 9119144, UI: 97169782